Arabic Arabic English English French French German German
dark

Oncopeptides phase 3 OCEAN study published in the Lancet Haematology

Oncopeptides AB announces that the data from the randomized head-to-head phase 3 OCEAN study, evaluating the efficacy and safety of melflufen plus dexamethasone versus pomalidomide plus dexamethasone in lenalidomide refractory patients with relapsed refractory multiple myeloma that have received 2-4 prior lines of therapy, have been published in the Lancet Hematology. Read More

Total
0
Shares
Leave a Reply

Your email address will not be published. Required fields are marked *

Previous Post

NeonMind Appoints Canadian Medical Leader in Anesthesiology, Dr. Daniel Bainbridge, MD, FRCPC to Its Specialty Clinics Advisory Board

Next Post

UNIST Partners with Yonsei University Health System to Empower Smart Healthcare

Related Posts
Total
0
Share